Clomid Side Effects: What the Label Trials Show, From Hot Flushes to Twins
SafeRxPills Pharmacy Team
Editorial team at SafeRxPills. Articles are written and checked against regulatory drug labelling (DailyMed, FDA, EMA) and published literature.

Clomid Fertility Treatment Guide: What Every Woman Needs to Know | SafeRxPills - pharmacy guide
In this article (23 sections)
Clomid (clomiphene citrate) is an oral tablet used to make the ovaries release an egg in women who do not ovulate regularly. Its side effects are usually mild: in the clinical studies behind the US label, the most reported problems were ovarian enlargement (13.6% of women) and hot flushes (10.4%), and most adverse reactions faded soon after the five-day course ended. A few effects need more attention: visual symptoms, ovarian hyperstimulation syndrome (OHSS) and the higher chance of twins.
This guide goes through each side effect with the numbers from the US prescribing information and from two large randomized trials, explains which symptoms mean you should stop and call a doctor, and lists who should not take clomiphene at all. We sell Indian clomiphene tablets, so we have a commercial interest; every figure below comes from the sources listed at the end. For dosing and buying questions, see our separate guide to buying Clomid online.
The short answer
The US label says that at recommended doses clomiphene "is generally well tolerated" and that adverse reactions "usually have been mild and transient and most have disappeared promptly after treatment has been discontinued."
- Most common: ovarian enlargement 13.6%, hot flushes 10.4%, abdominal or pelvic discomfort and bloating 5.5%.
- Less common: nausea and vomiting 2.2%, breast discomfort 2.1%, visual symptoms 1.5%, headache 1.3%, abnormal uterine bleeding 1.3%.
- Stop and seek care: any visual symptoms (blurring, spots, flashes), and abdominal pain or swelling, nausea, vomiting, diarrhea or weight gain, which are the early warning signs of OHSS listed on the label.
- Multiple pregnancy: 7.98% of pregnancies in the label trials were multiples, 6.9% twins.
Why clomiphene causes side effects
Clomiphene binds to estrogen receptors. The label lists the tissues it can act on: the hypothalamus, pituitary, ovary, endometrium (womb lining), vagina and cervix. In the brain, blocking estrogen feedback makes the pituitary release more of the hormones that drive follicle growth. That is the intended effect, and it also explains the main side effects.
- Lower estrogen signaling in the brain can bring hot flushes, much like those around menopause.
- Stronger stimulation of the ovaries can enlarge them, cause pelvic discomfort and, rarely, lead to OHSS.
- Stimulating more than one follicle raises the chance of twins.
- Effects on the womb lining appear in postmarketing reports as "reduced endometrial thickness."
Clomiphene is a mix of two forms of the same molecule: zuclomiphene and enclomiphene, with 30% to 50% zuclomiphene. In single-dose studies in volunteers, zuclomiphene had the longer half-life and stayed detectable for longer than a month. The label notes that some active drug may therefore remain in the body during early pregnancy in women who conceive during a treatment cycle.
Side effects in the label trials
The US label pools adverse events from clinical studies of 8,029 women. These are "adverse events": everything reported during treatment, whether or not the drug caused it. Here are all the events reported by more than 1% of women.
| Adverse event | Women reporting it |
|---|---|
| Ovarian enlargement | 13.6% |
| Vasomotor flushes (hot flushes) | 10.4% |
| Abdominal or pelvic discomfort, distention or bloating | 5.5% |
| Nausea and vomiting | 2.2% |
| Breast discomfort | 2.1% |
| Visual symptoms (blurred vision, lights, floaters, waves, light sensitivity, double vision, scotomata, phosphenes) | 1.5% |
| Headache | 1.3% |
| Abnormal uterine bleeding (spotting between periods, heavy periods) | 1.3% |
The label does not split these figures by dose, so it does not show whether 100 mg causes more of each event than 50 mg. It does say that visual symptoms become more frequent as the total dose or the length of treatment goes up.
Less common side effects
The label lists events that fewer than 1% of women reported in clinical trials:
- acute abdomen, constipation, diarrhea and increased appetite
- dermatitis or rash, hair loss or dry hair
- depression, nervous tension, insomnia, fatigue
- dizziness, light-headedness and vertigo
- more frequent or larger volumes of urination
- vaginal dryness
- weight gain or weight loss
Reports collected after approval include serious events such as stroke, seizure and pulmonary embolism. They also add other events, including fever, tinnitus, migraine, palpitations, high blood pressure, acne, hair growth, joint and muscle pain, raised liver enzymes and hepatitis. Because these come from voluntary reports, the label says it is not always possible to estimate how often they happen or to prove the drug caused them.
Hot flushes
Hot flushes were the second most common event in the label trials, at 10.4%. The label describes adverse reactions in general as mild and transient, with most disappearing promptly after treatment stops.
In the Legro trial of 750 women with polycystic ovary syndrome (PCOS), clomiphene was associated with a higher incidence of hot flushes than letrozole. The label lists vasomotor flushes, together with nausea, vomiting and visual blurring, among the symptoms seen when more than the recommended dose is taken. If flushes are severe or come with other symptoms, tell your prescriber.
Mood changes, anxiety and sleep
Mood effects are reported but not well counted. In the clinical trials, depression, nervous tension and insomnia each appeared in fewer than 1% of women. Postmarketing reports add anxiety, irritability, mood changes and psychosis, with no reliable frequency.
Fertility treatment itself is stressful, so it can be hard to separate a drug effect from the strain of trying to conceive. If you notice low mood, anxiety or sleep problems that are new or getting worse, tell your doctor. Any severe change in mood or thinking needs prompt medical care.
Ovarian enlargement and cysts
Ovarian enlargement was the most frequent event in the label trials (13.6%). The label explains that the largest enlargement "may not occur until several days after discontinuation" of the tablets, and that enlargement and cyst formation "usually regress spontaneously within a few days or weeks."
The rules on the label are specific:
- A pelvic examination is necessary before the first course and before each later course.
- If the ovaries enlarge, no more clomiphene should be given until they return to their pretreatment size, and the dose or length of the next course should be reduced.
- Cystic enlargement should be managed conservatively unless there is a surgical reason to operate.
- The patient should tell the doctor about any abdominal or pelvic pain, weight gain, discomfort or distention after taking clomiphene.
Ovarian hyperstimulation syndrome (OHSS)
The label does not give a rate for OHSS with clomiphene, but it treats it as a serious warning. It "may progress rapidly (within 24 hours to several days) and become a serious medical disorder." Some cases happened after repeated cycles of clomiphene or when it was combined with gonadotropin injections.
The early warning signs listed on the label are:
- abdominal pain and distention
- nausea, vomiting and diarrhea
- weight gain
Severe OHSS can cause large ovaries, fluid in the abdomen, shortness of breath, reduced urine output and fluid around the lungs. The label also lists blood clots, ovarian torsion, kidney failure and acute respiratory distress, and reports deaths from hypovolemic shock, hemoconcentration or thromboembolism. If conception happens, OHSS can quickly become severe.
Women with PCOS can be unusually sensitive. The label says they "should be started on the lowest recommended dose and shortest treatment duration for the first course of therapy." If you have the warning signs after a clomiphene cycle, contact your fertility clinic or seek urgent care the same day.
Visual symptoms: stop and get an eye exam
Visual symptoms were reported by 1.5% of women in the label trials. They include blurring, spots or flashes (scintillating scotomata), floaters, light sensitivity and double vision. The label says they appear to come from stronger and longer after-images, and often start or get worse in bright light.
The label is direct about what to do: "patients with any visual symptoms should discontinue treatment and have a complete ophthalmological evaluation carried out promptly." It also warns that:
- symptoms become more frequent with higher total dose or longer therapy
- they are usually reversible, but prolonged cases have been reported, some after stopping the drug
- they "may be irreversible, especially with increased dosage or duration of therapy"
- they may make driving or operating machinery more hazardous than usual, particularly in variable lighting
Two cases in the label show the time course. One woman taking 200 mg a day (twice the labeled maximum) developed blurring on day 7 and severe loss of acuity by day 10; her vision returned to normal 3 days after stopping. Another patient on prolonged treatment had flashes and blind spots that disappeared by day 32 after stopping. Postmarketing reports include cataract, optic neuritis, retinal hemorrhage and temporary or prolonged loss of vision, possibly irreversible.
Twins and other multiple pregnancies
Clomiphene can stimulate more than one follicle, which raises the chance of twins. In the label's clinical trials, 2,635 pregnancies were reported, and 7.98% of them were multiple pregnancies.
| Type of pregnancy | Share of reported pregnancies |
|---|---|
| Twins | 6.9% |
| Triplets | 0.5% |
| Quadruplets | 0.3% |
| Quintuplets | 0.1% |
| All multiple pregnancies | 7.98% |
Of the 165 twin pregnancies with enough information, identical and non-identical twins were in a ratio of about 1 to 5. Survival of babies from multiple births was 83.26%, against 98.16% for single births. A sextuplet birth was reported after the original studies; none of the six babies survived.
How clomiphene compares with injections
The AMIGOS trial randomized 900 women with unexplained infertility to clomiphene, letrozole or gonadotropin injections for up to four cycles. Among ongoing pregnancies, multiple gestation followed 8 of 85 clomiphene pregnancies, 9 of 67 letrozole pregnancies and 34 of 107 gonadotropin pregnancies. All multiples after clomiphene or letrozole were twins; gonadotropins produced 24 twin and 10 triplet gestations.
| Treatment (AMIGOS trial) | Multiple gestations | Rate |
|---|---|---|
| Clomiphene | 8 of 85 | 9.4% |
| Letrozole | 9 of 67 | 13.4% |
| Gonadotropin injections | 34 of 107 | 31.8% |
The label also says the higher chance of multiple pregnancy includes tubal pregnancies in both tubes, and a tubal pregnancy alongside one in the womb. Tubal pregnancy is also listed among postmarketing reports. Ask your clinic how early you will have an ultrasound once a test is positive.
Miscarriage, stillbirth and birth defects
In the label trials, among pregnancies with a known outcome, the miscarriage rate was 20.4% and the stillbirth rate was 1.0%. The miscarriage count included 28 ectopic pregnancies and 4 molar pregnancies. The label tells doctors to inform patients that "the available data suggest no increase in the rates of spontaneous abortion (miscarriage) or congenital anomalies with maternal clomiphene citrate use compared to rates in the general population."
The label adds a caveat: epidemiologic studies could only rule out large differences in risk, because there were few cases. Clomiphene is contraindicated in pregnancy, so a pregnancy test is needed before each new course. The label says each course may start as early as 30 days after the previous one, once pregnancy has been excluded.
Thinner womb lining
"Reduced endometrial thickness" appears among the label's postmarketing reports. Because clomiphene acts on estrogen receptors in the endometrium, a thin lining is a common worry for women who ovulate on clomiphene but do not conceive.
Data from the AMIGOS trial put this in perspective. In 2,459 insemination cycles, live birth rates were higher with a thicker lining, and a lining of 5 mm or less had an unadjusted risk ratio for live birth of 0.48 compared with 9 to 12 mm. After adjusting for which stimulation drug was used, the link was no longer statistically supported, and the authors noted appreciable live birth rates at every thickness, even 5 mm or less. Your clinic can measure the lining on the same scan that checks follicle size.
Triglycerides and pancreatitis
The label lists hypertriglyceridemia (high blood fats), in some cases with pancreatitis. The risk is higher with a personal or family history of high lipids and with higher than recommended doses or longer treatment. The label recommends:
- checking triglycerides before starting clomiphene
- periodic triglyceride monitoring for women with existing or family history of high lipids
The label also lists pancreatitis on its own among reported cases. Severe abdominal pain, especially with vomiting, needs urgent assessment.
Does clomiphene raise ovarian cancer risk?
The current US label states that prolonged use of clomiphene "may increase the risk of a borderline or invasive ovarian tumor," while noting that infertility itself is a primary risk factor for ovarian cancer.
Meta-analyses disagree. A 2023 review of 34 studies found that ovulation induction did not increase the risk of invasive or borderline ovarian tumors in most women, regardless of drug type or number of cycles, but nulliparous women (those who had never given birth) treated with ovulation induction showed a higher risk of borderline tumors. A 2025 review of 40 studies reported higher odds of invasive ovarian cancer (OR 1.23) and borderline tumors (OR 1.32) in women who used any fertility drug. The label separately recommends against treatment beyond about six cycles.
Side effects in men
Clomiphene is approved in the US only for ovulatory dysfunction in women. The label says there are "no adequate or well-controlled studies" showing that it works for male infertility, and that testicular tumors and gynecomastia (breast tissue growth) have been reported in men using it; the label says a cause and effect relationship with testicular tumors is not known. Any use in men is off-label and needs a doctor's supervision.
Who should not take clomiphene
The US label says clomiphene is contraindicated in:
- known hypersensitivity or allergy to clomiphene citrate or any of its ingredients
- pregnancy
- liver disease or a history of liver dysfunction
- abnormal uterine bleeding of undetermined origin
- ovarian cysts or enlargement not due to polycystic ovary syndrome
- uncontrolled thyroid or adrenal dysfunction
- an organic intracranial lesion such as a pituitary tumor
The label also advises caution with uterine fibroids, which may enlarge further, and notes that clomiphene may reduce milk supply. It cannot treat primary pituitary or ovarian failure. Other barriers to pregnancy, such as thyroid disease, high prolactin and male factor infertility, should be found and treated first. If high prolactin is the cause, see our cabergoline guide.
Dose, cycles and why the label sets limits
Many side effects depend on dose and how long treatment goes on, so the label keeps both low:
| Label rule | Detail |
|---|---|
| Starting dose | 50 mg once daily for 5 days |
| If no ovulation | 100 mg once daily for 5 days in the next course |
| Upper limit | More than 100 mg a day for 5 days is not recommended |
| Timing of ovulation | Most often 5 to 10 days after the last tablet |
| No ovulation after 3 courses | Further treatment not recommended; reevaluate |
| 3 ovulatory cycles without pregnancy | Further treatment not recommended |
| Total treatment | Not recommended beyond about 6 cycles |
When ovulation occurs at 50 mg, the label says there is no advantage to raising the dose in later cycles. If a period needs to be started before a course, our guide to the Provera withdrawal bleed explains how that works. If your plan includes a trigger shot, read our guide to the hCG trigger shot, which adds its own OHSS considerations.
Clomiphene vs letrozole side effects
Letrozole (Femara) is approved in the US only for breast cancer. Its use for ovulation induction is off-label. It is still widely compared with clomiphene because of the Legro trial, which randomized 750 women with PCOS to either drug for up to five cycles.
| Outcome (Legro 2014, PCOS) | Clomiphene | Letrozole |
|---|---|---|
| Ovulation per treatment cycle | 48.3% (688 of 1,425) | 61.7% (834 of 1,352) |
| Cumulative live birth | 19.1% (72 of 376) | 27.5% (103 of 374) |
| Pregnancy loss | 29.1% (30 of 103) | 31.8% (49 of 154) |
| Twin pregnancy | 7.4% | 3.4% |
| Side effects more common | Hot flushes | Fatigue and dizziness |
The differences in pregnancy loss and twins were not statistically significant, and other adverse events were similar between the groups. In the AMIGOS trial of unexplained infertility, live birth was 23.3% with clomiphene and 18.7% with letrozole, and clinical pregnancy rates with the two drugs did not differ significantly (P=0.10). The best choice depends on the cause of infertility, which is a decision for your fertility doctor. For PCOS background, see our metformin for PCOS guide.
When to call a doctor
Contact your prescriber or fertility clinic promptly if you have:
- any change in vision: blurring, spots, flashes, floaters or light sensitivity (stop the tablets)
- abdominal or pelvic pain, swelling or distention
- nausea, vomiting or diarrhea after a course, or rapid weight gain
- shortness of breath or reduced urination (seek emergency care)
- severe abdominal pain with vomiting
- a positive pregnancy test with one-sided pelvic pain or bleeding
- new or worsening low mood, anxiety or confusion
Practical steps to reduce problems
- Have the pelvic examination the label calls for before each course (your clinic may also scan).
- Take a pregnancy test before each new course.
- Ask for a triglyceride test before starting if it has not been done.
- Avoid driving at night or in changing light if your vision feels off, and stop the tablets.
- Track ovulation with the method your doctor suggests; the label mentions a basal body temperature chart.
- Keep a short symptom diary for each cycle so your prescriber can adjust the dose or length of the next course.
- If ovulation is confirmed, ask whether you need progesterone luteal phase support.
Clomiphene tablets we sell
Clomiphene is a prescription medicine in the US. These are the clomiphene citrate tablets we list, with prices as of 31 October 2026:
| Product | Pack | Price | Per tablet |
|---|---|---|---|
| Siphene 50 mg (Serum Institute India) | 30 tablets | $22.50 | $0.75 |
| Siphene 50 mg | 60 tablets | $36.25 | $0.60 |
| Siphene 100 mg (Serum Institute India) | 30 tablets | $33.00 | $1.10 |
| Siphene 100 mg | 60 tablets | $52.50 | $0.88 |
| Clofert 25 mg (Maneesh Pharmaceuticals) | 60 tablets | $22.50 | $0.38 |
| Clofert 25 mg | 90 tablets | $31.25 | $0.35 |
The US label strength is 50 mg, and the label dose starts at 50 mg. A 25 mg tablet only fits a dose your prescriber has chosen. For comparison, the federal NADAC survey for the week of 28 October 2026 put the national average acquisition cost of a generic clomiphene 50 mg tablet at about $4.06 (median across 11 NDCs), before dispensing fees and margin. Our female infertility page lists related treatments.
Related guides
- Buy Clomid online: dosage, safety and fertility guide
- The hCG trigger shot and the 36 hour window
- Progesterone for luteal phase support
- Provera and the progestin withdrawal bleed
- Metformin for PCOS
- Cabergoline: what it treats and how to dose it
Sources
- Clomid (clomiphene citrate) tablets USP 50 mg, US prescribing information, Cosette Pharmaceuticals, Inc., DailyMed setid 2ca373c1-4dba-4126-8616-5c533d606fe5 (version published February 2025): Description, Clinical Pharmacology, Clinical Studies, Indications and Usage, Contraindications, Warnings, Precautions, Adverse Reactions (Table 2), Dosage and Administration.
- Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014;371(2):119-29. PMID 25006718.
- Diamond MP, Legro RS, Coutifaris C, et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med 2015;373(13):1230-40. PMID 26398071.
- Quaas AM, Gavrizi SZ, Peck JD, et al. Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes. Fertil Steril 2021;115(1):213-220. PMID 32972733.
- Yu L, Sun J, Wang Q, et al. Ovulation induction drug and ovarian cancer: an updated systematic review and meta-analysis. J Ovarian Res 2023;16(1):22. PMID 36694251.
- Li H, Hu Z, Fan Y, et al. Ovarian-stimulating drug use and risk of ovarian tumor in infertile women: a meta-analysis. Int J Gynecol Cancer 2025;35(2):100046. PMID 39971432.
- Femara (letrozole) US prescribing information, Novartis, via openFDA (effective 11 June 2026): Indications and Usage.
- Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC), clomiphene citrate 50 mg tablet, week of 28 October 2026.
This guide is for information and does not replace advice from a doctor who knows your medical history. Fertility drugs should be used only under the supervision of a doctor experienced in treating ovulation disorders.
?Frequently Asked Questions
What are the most common side effects of Clomid?
In the clinical studies behind the US label (8,029 women), the most reported adverse events were ovarian enlargement (13.6%), hot flushes (10.4%) and abdominal or pelvic discomfort, distention or bloating (5.5%). Nausea and vomiting (2.2%), breast discomfort (2.1%), visual symptoms (1.5%), headache (1.3%) and abnormal uterine bleeding (1.3%) were less common.
How long do Clomid side effects last?
The label says adverse reactions have usually been mild and transient and most disappeared promptly after treatment stopped. Ovarian enlargement may peak several days after the last tablet and usually settles within a few days or weeks. Visual symptoms are usually reversible but can be prolonged, and the label says they may be irreversible, especially with higher doses or longer treatment.
Does Clomid cause twins?
It raises the chance. In the label trials, 7.98% of 2,635 reported pregnancies were multiples: 6.9% twins, 0.5% triplets, 0.3% quadruplets and 0.1% quintuplets. In the AMIGOS trial of unexplained infertility, 8 of 85 ongoing clomiphene pregnancies (9.4%) were twins, compared with 34 of 107 (31.8%) multiples after gonadotropin injections.
Can Clomid damage your eyes?
Visual symptoms such as blurring, spots or flashes occurred in 1.5% of women in the label trials. They are usually reversible, but the label says prolonged cases have been reported and that they may be irreversible, especially with higher doses or longer use. Anyone with visual symptoms should stop clomiphene and have a complete eye examination promptly.
What are the warning signs of OHSS on Clomid?
The label lists abdominal pain and distention, nausea, vomiting, diarrhea and weight gain as early warning signs of ovarian hyperstimulation syndrome. It can progress within 24 hours to several days and become serious, especially if conception occurs. Shortness of breath or reduced urine output needs emergency care.
Does Clomid cause mood swings?
Depression, nervous tension and insomnia were each reported by fewer than 1% of women in the clinical trials. Reports after approval add anxiety, irritability, mood changes and psychosis, but the label cannot give a reliable frequency for these. Tell your doctor about any new or worsening mood symptoms.
Does Clomid cause weight gain?
Weight gain or loss was reported by fewer than 1% of women in the label trials. Sudden weight gain after a course, especially with abdominal swelling or pain, can be an early sign of OHSS and should be reported to your doctor straight away.
Does Clomid increase the risk of miscarriage?
The label says available data suggest no increase in miscarriage or birth defect rates with clomiphene compared with the general population. In the label trials the miscarriage rate among pregnancies with a known outcome was 20.4% and the stillbirth rate 1.0%. The label notes that the higher chance of multiple pregnancy includes tubal pregnancies in both tubes, or one in a tube alongside one in the womb.
Are side effects worse at 100 mg than at 50 mg?
The label's adverse event table is not split by dose. It does say visual symptoms become more frequent with a higher total dose or longer treatment, and it recommends the lowest effective dose to limit ovarian enlargement. More than 100 mg a day for 5 days is not recommended, and treatment beyond about six cycles is not recommended.
Can I drive while taking Clomid?
Most women can, but the label warns that visual symptoms may make driving or operating machinery more hazardous than usual, particularly in variable lighting. If you notice blurring, spots or flashes, do not drive, stop the tablets and arrange an eye examination.
Does letrozole have fewer side effects than Clomid?
In the Legro trial of 750 women with PCOS, hot flushes were more common with clomiphene, while fatigue and dizziness were more common with letrozole; other adverse events were similar. Twin pregnancy was 7.4% with clomiphene and 3.4% with letrozole, a difference that was not statistically significant. Letrozole is approved in the US only for breast cancer, so its use for ovulation is off-label.
SafeRxPills Pharmacy Team
Pharmacist, Content, B.Pharm, M.Pharm, Rajiv Gandhi University
Pharmacist writing on antiparasitic, ophthalmic and dermatological generics. Focuses on what the regulatory labelling and published evidence actually support.
Comments (0)
Leave a Comment
No comments yet. Be the first to share your thoughts!
Related Articles

Visanne (Dienogest 2 mg) for Endometriosis: Trial Results, Side Effects and Where It Is Available
October 17, 2026


Metformin for PCOS: Complete Treatment Guide for Women with Polycystic Ovary Syndrome
April 30, 2026
